Related Experiment Video
Updated: Jul 19, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Fatal adenoviral hepatitis after rituximab therapy
Anita Iyer1, Radhika Mathur, Banglore V Deepak
1Department of Pathology, Yale University School of Medicine, New Haven, Conn 06520-8023, USA.
Abstract:
Rituximab is an anti-CD20 monoclonal antibody used in the treatment of B-cell proliferative disorders. Although it is very effective in many cases, a number of case reports in the literature have described fatal viral reactivations associated with rituximab therapy. We report what is to our knowledge the first case of fatal adenoviral hepatitis in a patient with Waldenstrom macroglobulinemia treated with rituximab. This case is a new example of an emerging pattern of association between rituximab therapy and fatal viral reactivations, and it urges increased vigilance when using rituximab-based treatment regimens.
Related Concept Videos
Myocarditis III: Medical Management
Respiratory Syncytial Virus Disease
Hepatitis
Rheumatic Heart Disease I: Introduction
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
